drugset / Trial / NCT06735144
Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), recommended dose for phase II clinical trials (RP2D), and preliminary efficacy.
Timeline
- Start
- 2024-12-23
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FH-006 | Unknown | — | Intravenous |